Navigation Links
Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea
Date:8/5/2010

MALVERN, Pa., Aug. 5 /PRNewswire/ -- Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results today from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

The double-blinded, placebo-controlled, crossover clinical trial of 22 patients with rosacea was designed to evaluate the bioavailability of V-101 and provide preliminary evidence of efficacy as measured by improvement in moderate to severe erythema, the bright redness of the skin associated with rosacea.  V-101 had a side effect profile similar to placebo and V-101's active ingredient was not detectable in study participants' plasma, a strong indication of the product's overall tolerability and safety profile.  Additionally, the study results were positive for all endpoints, demonstrating a clinically and statistically significant improvement in treating the erythema associated with rosacea.

"This important study demonstrated that V-101 has a good safety profile and provides statistically significant evidence of effectiveness in treating the erythema of rosacea," said Dr. Neal Walker, president and chief executive officer of Vicept. "We look forward to advancing our clinical program into Phase II and continuing our efforts to develop this product for the 16 million people in the United States who live with this common, chronic skin condition every day."

"Rosacea is devastating to people who live with it and the primary complaint is erythema, the red sunburn appearance that accompanies the disease," said James Leyden, M.D., Professor Emeritus, University of Pennsylvania and lead investigator. "To date, there are no FDA approved treatments for this manifestation of the disease and V-101 offers a novel approach that, if successful, would address this unmet medical need."

About Rosacea

Rosacea is a common, chronic condition of the skin that is estimated to affect more than 16 million people in the United States and more than 45 million people worldwide. The disorder appears most commonly in fair-skinned individuals of northern, eastern European or Celtic origin between 30 and 50 years of age, and women are affected 2-3x more often than men. Rosacea typically occurs in a central facial distribution (cheeks, nose, forehead, and chin) and is most commonly associated with a history of flushing or blushing (transient erythema), persistent facial redness (nontransient erythema), papules and/or pustules which may resemble acne, and facial telangiectasias (dilated blood vessels). Each of these signs may be transient or persistent and may occur individually or in combination.

About Vicept

Vicept Therapeutics, Inc. is a privately held specialty pharmaceutical company with a mission to develop the first effective topically applied therapy directed toward the erythema of rosacea and other disorders characterized by redness and or flushing of the skin. The company is also pursuing the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin.  The company is based in Malvern, Pennsylvania and more information can be found by visiting the company's website at www.vicepttx.com.


'/>"/>
SOURCE Vicept Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
2. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
3. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
4. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
5. Talecris Biotherapeutics Announces Premerger HSR Filing
6. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
7. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
11. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Cupertino, CA (PRWEB) , ... February 08, 2016 ... ... and multilingual testing services, announced today the launch of its revamped and ... range of scalable language service solutions, the redesigned website will better communicate how ...
(Date:2/9/2016)... ... February 09, 2016 , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre ... will focus on acquiring new accounts and work closely with existing Tunnell clients throughout ... brings to our European clients more than 15 years of experience in the pharmaceutical ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... the years and Open Access publishing is one of the popular publication models ... open access journals and 3000+ International Conferences across the ...
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
(Date:1/25/2016)... BELL, Pa. , Jan. 25, 2016   Unisys Corporation ... recognition system at John F. Kennedy (JFK) International Airport, ... Border Protection (CBP) identify imposters attempting to enter ... do not belong to them. pilot testing of ... out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):